New data fails to quiet cholesterol drug debate
CHICAGO (Reuters) - New data about the controversial cholesterol fighter Vytorin failed to quell concerns that the drug might not be as good as thought at keeping heart disease at bay, leading an expert panel to recommend on Sunday that patients stick with statins.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=B5ZizQ" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=B5ZizQ)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=lLFF51F" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=lLFF51F) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=KTZY5Mf" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=KTZY5Mf) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=LYWntif" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=LYWntif)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/260916874" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/260916874/idUSN3034235420080330